Bruce Strober

1. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
   2022/11/29 by Georgios Kokolakis, Richard B. Warren, Richard B Warren +16 · 9 citations
   Immunology and Microbiology · Medicine · Biochemistry, Genetics and Molecular Biology · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Inflammatory Bowel Disease
2. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
   2023/01/01 by Bruce Strober, Diamant Thaçi, Howard Sofen +13 · 1 citation